Malignant Pleural Mesothelioma
Associated Genetic Biomarkers
Malignant pleural mesotheliomas most frequently harbor alterations in BAP1, NF2, CDKN2A, CDKN2B, and TP53 .
CDKN2A Loss, CDKN2B Loss, BAP1 Mutation, BAP1fs, and NF2 Mutation are the most common alterations in malignant pleural mesothelioma .
There are 32 clinical trials for malignant pleural mesothelioma, of which 27 are open and 5 are completed or closed. Of the trials that contain malignant pleural mesothelioma as an inclusion criterion, 20 are phase 1 (17 open), 8 are phase 1/phase 2 (8 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open).
MSLN, NF2, and WT1 are the most frequent gene inclusion criteria for malignant pleural mesothelioma clinical trials .
Pembrolizumab, pemetrexed, and cisplatin are the most common interventions in malignant pleural mesothelioma clinical trials.
Significant Genes in Malignant Pleural Mesothelioma
NF2 is altered in 28.41% of malignant pleural mesothelioma patients .
NF2 is an inclusion eligibility criterion in 2 clinical trials for malignant pleural mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain NF2 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.